Inhibition of mammary carcinogenesis of dimethylbenzanthracene treated rats with a brominated triphenylethylene.
Daily administration of a brominated triphenylethylene (TBP), to rats which received 20 mg of DMBA p. o. inhibits mammary carcinogenesis. The effect appears even with very small doses (i ppm in the diet) and seems to be dose related. With one exception (an adenofibroma) the tumours in control and treated animals were malignant. Administration of TBP prevents the appearance of corporea lutea in the ovaries but not the usual necrosis of the adrenal cortex.
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000037:antagonists & inhibitors*; D000230:Adenocarcinoma / Q000517:prevention & control; D000232:Adenofibroma / Q000517:prevention & control; D000302:Adrenal Cortex / Q000473:pathology; D000818:Animals; D001551:Benz(a)Anthracenes / Q000037:antagonists & inhibitors*; D003338:Corpus Luteum / Q000187:drug effects; D045166:Estradiol Congeners / Q000494:pharmacology*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000517:prevention & control*; D009336:Necrosis / Q000139:chemically induced; D009929:Organ Size / Q000187:drug effects; D010053:Ovary / Q000473:pathology; D051381:Rats; D013267:Stilbenes / Q000494:pharmacology*
D001551:Benz(a)Anthracenes; D045166:Estradiol Congeners; D013267:Stilbenes; D015127:9,10-Dimethyl-1,2-benzanthracene